Related Party Transactions |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Related Party Transactions [Abstract] | |
| Related Party Transactions | Related Party Transactions Related Party Agreements License Agreement with Yale University On September 30, 2013, the Company entered into the Yale Agreement with Yale University (see Note 11, "License, Acquisitions and Other Agreements"). The Company’s Chief Executive Officer ("CEO") is one of the inventors of the patents that the Company has licensed from Yale University and, as such, is entitled to a specified share of the glutamate product-related royalty revenues that may be received by Yale University under the Yale Agreement. In January 2021, the Company entered into the Yale MoDE Agreement with Yale University (see Note 11, "License, Acquisitions and Other Agreements," for details). Under the license agreement, the Company acquired exclusive, worldwide rights to Yale University's intellectual property directed to its MoDE platform. For the three and six months ended June 30, 2026, the Company recorded $716 and $1,491, respectively, in R&D expense, including certain administrative expenses, related to the Yale MoDE Agreement and the Yale Agreement (collectively, the "Yale Agreements"). For the three and six months ended June 30, 2025, the Company recorded $330 and $851, respectively, in R&D expense, including certain administrative expenses, related to the Yale Agreements. As of June 30, 2026, the Company did not owe any amounts to Yale University.
|